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Typhoid and Paratyphoid Cost of Illness in Pakistan: 
Patient and Health Facility Costs From the Surveillance for 
Enteric Fever in Asia Project II
Nelly Mejia,1,  Farah Qamar,2 Mohammad T. Yousafzai,2 Jamal Raza,3 Denise O. Garrett,4 Kashmira Date,1 Taiwo Abimbola,1 and Sarah W. Pallas1
1Global Immunization Division, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA, 2Aga Khan University, Karachi, Pakistan, 3National Institute of Child Health, Karachi, Pakistan, 
and 4Applied Epidemiology, Sabin Vaccine Institute, Washington, DC, USA
Background. The objective of this study was to estimate the cost of illness from enteric fever (typhoid and paratyphoid) at 
selected sites in Pakistan.
Methods. We implemented a cost-of-illness study in 4 hospitals as part of the Surveillance for Enteric Fever in Asia Project 
(SEAP) II in Pakistan. From the patient and caregiver perspective, we collected direct medical, nonmedical, and indirect costs per 
case of enteric fever incurred since illness onset by phone after enrollment and 6 weeks later. From the health care provider perspec-
tive, we collected data on quantities and prices of resources used at 3 of the hospitals, to estimate the direct medical economic costs 
to treat a case of enteric fever. We collected costs in Pakistani rupees and converted them into 2018 US dollars. We multiplied the unit 
cost per procedure by the frequency of procedures in the surveillance case cohort to calculate the average cost per case.
Results. We collected patient and caregiver information for 1029 patients with blood culture–confirmed enteric fever or with a 
nontraumatic terminal ileal perforation, with a median cost of illness per case of US $196.37 (IQR, US $72.89–496.40). The median 
direct medical and nonmedical costs represented 8.2% of the annual labor income. From the health care provider perspective, the 
estimated average direct medical cost per case was US $50.88 at Hospital A, US $52.24 at Hospital B, and US $11.73 at Hospital C.
Conclusions. Enteric fever can impose a considerable economic burden in Pakistan. These new estimates of the cost of illness 
of enteric fever can improve evaluation and modeling of the costs and benefits of enteric fever prevention and control measures, in-
cluding typhoid conjugate vaccines.
Keywords.  typhoid; paratyphoid; enteric fever; cost of illness; Pakistan.
Enteric fever, an infection caused by S. Typhi or Paratyphi, is 
endemic in many low- and middle-income tropical countries 
among populations with low access to safe water and sanitation. 
Globally, in 2017 there were an estimated 10.9 million cases of 
typhoid fever and 3.4 million cases of paratyphoid fever [1]. 
The economic costs of any disease, including enteric fever, com-
prise the direct medical and nonmedical costs associated with 
seeking and receiving care, as well as the indirect costs of pro-
ductivity loss due to illness or death, which are borne by house-
holds, health systems, and governments [2]. Growing trends 
of antibiotic resistance of S. Typhi and Paratyphi increase the 
economic costs of enteric fever by requiring more potent and 
expensive drugs for treatment [3].
Pakistan is a lower-middle income country with a popula-
tion of 212 million [4]. Enteric fever is endemic in Pakistan, 
with an estimated incidence of 727.8 thousand cases and 8175 
deaths in 2017 [5], with a growing trend of antibiotic-resistant 
enteric fever. Since November 2016, Pakistan has faced an out-
break caused by an extensively drug-resistant (XDR) typhoid 
strain (resistant to cotrimoxazole, ampicillin, chloramphen-
icol, and ceftriaxone, and resistant to or with reduced suscep-
tibility to fluoroquinolones) [6]. There has been only 1 cost of 
illness (COI) study of typhoid fever in Pakistan; however, the 
sample size was small and purposive (n = 66 pediatric patients 
with a positive blood culture test for typhoid), and the data 
were collected in 2001 [7]. Similarly, there are COI studies of 
typhoid fever in other Asian countries (China, India, Indonesia, 
Nepal, and Vietnam) with data collected more than 17  years 
ago, between 1995 and 2003, and 1 in Nepal in 2015 that col-
lected qualitative data [7–9]. These earlier studies might not 
reflect current health  care and pricing structures in Pakistan. 
Moreover, except for the studies in Bangladesh and Nepal in 
2018 from the Surveillance for Enteric Fever in Asia Project 
(SEAP) II, also included in this Supplement [10, 11], existent 
studies only included typhoid fever patients, excluding par-
atyphoid fever patients and those with severe illness, such as 
nontraumatic terminal ileal gastrointestinal perforations with 
no known etiology, if not lab confirmed; they also did not 
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report information about specific treatment procedures for ty-
phoid and paratyphoid.
This study aims to fill this gap in the evidence base for 
Pakistan. Results of these COI estimates can help evaluate in-
vestments in health policy interventions aiming to control and 
eliminate enteric fever, such as the introduction and scale-up of 
the new typhoid Vi-conjugate vaccine—recommended by the 
World Health Organization (WHO) and begun in Pakistan in 
2019—and improvements in access to safe water and sanitation 
[6, 12]. Using data from SEAP II, we present detailed COI esti-
mates at the procedure level for both typhoid and paratyphoid 
fever cases from 2 perspectives: (1) the patient and caregiver; 
and (2) the health care provider.
METHODS
Study Setting
This COI study was conducted as part of the economic compo-
nent of SEAP II at 4 hospitals in urban areas of Karachi, in the 
Sindh Province of Pakistan. These health facilities included a 
public, not-for-profit pediatric hospital with teaching status; 2 
private, not-for-profit teaching hospitals; and a public teaching 
hospital. These hospitals were purposively selected based on 
their laboratory capacity to perform blood culture testing for 
typhoid and paratyphoid, and they were not intended to be 
representative of health facilities at any geographical level in 
Pakistan.
Cost of Illness From the Patient and Caregiver Perspective
Study Design
Patients were recruited in 3 hospitals between September 2016 
and December 2018, and in a fourth hospital later added to 
the SEAP II study between January 2018 and December 2018. 
Eligible patients had a positive blood culture test for S. Typhi 
or Paratyphi or a nontraumatic terminal ileal perforation with 
no other known etiology, regardless of the blood culture result.
The COI evaluation from the patient and caregiver perspec-
tive included direct medical and nonmedical costs paid by any 
funding source, as well as indirect costs. Direct medical costs 
were defined as the monetary value of health facility registra-
tion fees, clinical examinations, inpatient stays, laboratory tests, 
drugs and medications, and other diagnostic and treatment 
services (eg, X-ray, surgery). Direct nonmedical costs were de-
fined as the monetary value of transport, food, lodging, and 
care services for family members. Indirect costs were comprised 
of school days missed by patients and work time (including sick 
leave) lost by patients and caregivers (accompanying/providing 
care) due to the episode of enteric fever. School days missed 
were not monetized. Work productivity lost was only mon-
etized for patients and caregivers ≥18  years at the median of 
the wage range reported (eg, if the monthly salary reported 
was in the range of 0–2400 Pakistani rupees, the midpoint of 
this range—1200 rupees—was used to value the work time). 
Costs excluded were the expenses on drugs, diagnostics, and 
treatments not related to enteric fever (eg, comorbidities and 
chronic conditions), goods and services that patients received at 
no charge, and intangible costs of pain and suffering.
Data Collection
Cost data questionnaires were designed in English and, after 
being piloted in the sites, were translated into Urdu. Bilingual 
SEAP II interviewers administered the questionnaires in Urdu 
and recorded the data electronically in a tablet. Cost data were 
collected at 2 time points by telephone: the first questionnaire 
was administered 2 to 3 days after a blood culture result or hos-
pital discharge, if the patient received inpatient care; and the 
second questionnaire was administered 6 weeks (approximately 
42 days) after study enrollment, at the same time as the SEAP 
II surveillance component follow-up call. The first question-
naire collected data on expenses incurred by the patient and 
caregivers from illness onset through the patient’s return home 
after the enrollment visit; the second questionnaire collected 
costs incurred after the enrollment visit until the follow-up 
call. Respondents were either patients ≥16 years or caregivers 
≥18 years.
Cost of Illness Measures and Data Analysis
From the patient and caregiver perspective, COI measures in-
cluded the median direct medical and nonmedical costs, me-
dian number of days of school lost by patients, median number 
of days of work lost and sick leave used by patients and/or care-
givers, median wages lost by the patient and/or caregiver, and 
median total COI during the episode of enteric fever (sum of 
the direct medical costs, direct nonmedical costs, and indirect 
costs). For all COI measures, the median and the interquartile 
range were calculated.
The main analysis included COI measures for patients with 
enteric fever (typhoid and paratyphoid cases and nontraumatic 
terminal ileal perforation cases combined). In the main anal-
ysis, the value of the time spent by caregivers who did not reg-
ularly earn a wage (eg, unpaid household labor) only included 
the time spent at health facilities caring for or accompanying 
the patient, and was not monetized. In addition, as the value 
of the sick leave taken could have been borne by the employers 
and not by the employees, the main analysis also presented a 
COI estimate without the value of sick leave.
Sensitivity analyses were conducted to calculate COI 
measures separately for typhoid, paratyphoid, surgical, and 
nonsurgical cases, as well as those with multidrug-resistant 
(MDR) S. Typhi and S. Paratyphi (exclusively resistant to am-
picillin, chloramphenicol, and cotrimoxazole) or XDR S. Typhi 
(XDR S. Paratyphi was excluded because there were no XDR 
cases). In addition, sensitivity analyses were conducted without 
outliers for each cost category (eg, examination fee, drugs, 
transportation). Outliers were defined as the observations with 
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values above or below 2.24 standard deviations from the mean 
[13]. Other sensitivity analyses were conducted to estimate the 
indirect costs of patients and caregivers under different wage 
assumptions to address unpaid labor by (1) imputing their wage 
with the minimum daily wage rate of 675 rupees (or US $5.56 
[14]); and (2) with the median wage reported by the respond-
ents with paid labor. Finally, a sensitivity analysis to estimate the 
lifetime indirect costs of patients who died was also included. 
The value of a patient’s future earnings were calculated using 
the average life expectancy in Pakistan as reported by the WHO 
[15], and using the minimum wage rate as a proxy for income, 
adjusted by an annual inflation rate of 3.66% (the average an-
nual inflation rate in Pakistan between 2016–2018 [16]) and 
discounted at a standard annual rate of 3% [2].
Costs were collected in Pakistani rupees, adjusted to 2018 
values based on inflation rates and converted into 2018 US dol-
lars using the annual average exchange rate for 2018 (121.48 
rupees per US dollar [17]). Missing wage information for pa-
tients or caregivers was imputed with the median wage of the 
respondent sample.
Cost of Illness From the Health Care Provider Perspective
Study Design
From the health care  provider perspective, the COI was esti-
mated as the direct medical economic costs (ie, the value of 
all resources used, not only financial outlays) incurred by the 
health facility to diagnose and treat a patient with enteric fever 
and its complications. The health facility sample included 3 
of the 4 health facilities participating in the SEAP II surveil-
lance and the patient and caregiver COI studies: a public, 
not-for-profit pediatric hospital with teaching status, and 2 pri-
vate, not-for-profit teaching hospitals. The fourth hospital was 
added to SEAP II in January 2018, too late to be included in 
the health care provider perspective evaluation. Activity-based 
macro-costing was used to estimate the cost of procedures for 
which resource use per unit was assumed not to differ between 
patients with enteric fever and patients with other diseases (ex-
cluding medication costs)—for example, outpatient visits, inpa-
tient bed days, emergency visits, pediatric intensive care unit 
bed days, intensive care unit bed days, outpatient surgery visits, 
inpatient surgery bed days—as well as to allocate the value of 
administrative services (eg, security, marketing, etc.), utilities 
and communications (eg, gas, electricity, water), and cross-
cutting clinical supporting services (laundry, cleaning, etc.). 
Ingredients-based micro-costing was used to estimate the costs 
of specific procedures for which activity-based macro-costing 
by ward could not be conducted because the resource use per 
unit varied by procedure: blood draws, blood culture tests, com-
plete blood counts, abdominal X-rays, abdominal ultrasounds, 
surgeries for intestinal perforation, and gallbladder surgeries.
Resource inputs included in the cost estimation were per-
sonnel time and salaries, materials and supplies, equipment 
and instruments, contracted services, and the equivalent rental 
value of the building space. Excluded costs were those associ-
ated with magnetic resonance imaging, computed tomography 
scans, Widal tests, and C-reactive protein tests (reportedly in-
frequently used for enteric fever diagnosis in the study sites); pa-
tient registration; medication costs paid for by patients (rather 
than by the hospital as part of procedure provision); costs unre-
lated to enteric fever (eg, anti-malarial treatment, comorbidities, 
chronic conditions); nonclinical costs (eg, teaching salaries 
and classroom space) for the medical-school aspects of these 
teaching hospital sites; evaluation-specific costs; and the value 
of the study team staff time for project management, technical 
assistance, and evaluation.
Data Collection
Data on prices and quantities of resources used, as well as ser-
vice volumes, for the 2015–2016 fiscal year were collected using a 
Microsoft Excel tool that had been piloted in the sites. Data were 
collected between June 2017 and April 2018 from annual finan-
cial reports, administrative records, on-site observation, and inter-
views with administrative and medical staff by a local consultant 
economist and by local SEAP II study team staff, with technical 
assistance from US Centers for Disease Control and Prevention 
(CDC) staff. Missing prices of supplies and materials or equipment 
and instruments were imputed with data from the United Nations 
International Children’s Emergency Fund (UNICEF) supply catalog 
[18]; if prices were unavailable from UNICEF, they were imputed 
from the other SEAP II hospitals in Pakistan. Data on the frequen-
cies of procedures conducted for the patients with blood culture–
confirmed enteric fever or nontraumatic ileal perforation in these 
health facilities were collected through the SEAP II surveillance 
component during September 2016–December 2018.
Cost-of-Illness Measures and Data Analysis
Data were analyzed in Microsoft Excel. For procedure costs 
estimated using ingredients-based micro-costing (and for the 
personnel costs of general services not specific to enteric fever), 
the unit cost per clinical procedure was calculated as the sum of 
the products of the quantity of resources used in that procedure, 
multiplied by that resource’s price (or monetary value):
=
N∑
j=1
(quantity of resource input usedij ∗ price of resource inputj)
Here, i is the procedure, and j indexes each resource input used 
in the procedure up to N resources.
Due to the lack of information disaggregated at the ward 
level, for procedure costs estimated using activity-based macro-
costing, the monetary value of resources (eg, supplies and ma-
chinery), except personnel, used in that procedure over the 
fiscal year was calculated as the sum of the products of the 
quantity of resources used in the whole hospital, multiplied by 
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that resource’s price (or monetary value) and then divided by 
the hospital’s service volume (total number of services). Thus, 
the value of resources was evenly allocated across all services:
=
∑N
j=1(quantity of resource input usedj ∗ price of resource inputj)
service volume
Here, j indexes each resource input used in the hospital up to 
N resources.
As most information about administrative costs in the 3 hos-
pitals was missing—namely, hospital-level cross-cutting util-
ities and communication services, administrative services, and 
clinical support services (eg, laundry, cleaning)—these costs 
were imputed. All procedure costs were increased by the pro-
portion that those administrative costs represented as part of 
the nonadministrative costs by micro-costing or activity-based 
procedures across the 4 participating hospitals in SEAP II in 
Nepal and Bangladesh, which had more complete information. 
Thus, the estimated costs of procedures using ingredients-based 
micro-costing were increased by 36%, and the estimated costs 
of activity-based procedures were increased by 20%.
The average direct economic medical cost per case of enteric fever 
was calculated by multiplying the unit cost per clinical procedure by 
the procedure’s frequency in the patient cohort of enteric fever cases 
identified through blood culture confirmation or nontraumatic ileal 
perforation from the surveillance study component, regardless of 
their participation in the patient COI component. These costs were 
summed across all procedures, then divided by the number of en-
teric fever cases from the surveillance component:
=
∑K
k=1(health facility unit cost procedurei ∗ frequency of procedureik)
Total number of confirmed enteric fever cases (K)
Here, i is the procedure, k indexes the confirmed enteric fever cases 
at the health facility, and K is the total number of enteric fever cases 
identified at the health facility during the surveillance study period.
Health facility costs were collected in the local currency 
(Pakistani rupees), adjusted to 2018 values based on inflation 
rates from the Pakistan Bureau of Statistics [16], and converted 
into US dollars using the average exchange rate for 2018 (121.48 
Pakistani rupees per US dollar [17]).
Ethical Considerations
The study protocol was approved by the Pakistan Ethical Review 
Committee. In accordance with the human subjects review pro-
cedures of the US CDC, it was determined that the CDC was 
not formally engaged in human subjects research.
RESULTS
Cost of Illness From the Patient and Caregiver Perspective
Patient Characteristics
The first cost questionnaire captured responses from 1029 el-
igible patients or their caregivers (Table  1). Of these, 746 re-
sponded to the second questionnaire, for a 72.5% response rate. 
Table 1. Patient and Caregiver Cost of Illness Due to Enteric Fever, 
Sample Characteristics, Karachi, Pakistan, September 2016–December 
2018
Characteristic n %
Respondents
Patients responding to enrollment cost questionnaire 1029 100.0
Patients responding to 6-week follow-up cost questionnaire 746 72.5
Patients who died of enteric fever 1 0.1
Blood culture result
Salmonella Typhi positive 807 78.4
Salmonella Paratyphi positive 95 9.2
Not positive for either Salmonella Typhi or Paratyphi
 (surgical cases)
127 12.3
Drug resistance of Salmonella Typhi or Salmonella Paratyphi 
positive cases, n = 902
Multidrug-resistanta Salmonella Typhi or Salmonella
 Paratyphi positive 
170 18.8
Extensively drug-resistantb Salmonella Typhi positive 401 44.5
No drug–resistant Salmonella Typhi or Salmonella
 Paratyphi positive
331 36.7
Age, years
<2 107 10.4
2–4 203 19.7
5–17 450 43.7
18+ 269 26.1
Sex
Male 624 60.6
Female 405 39.4
Household with mobile phone
Yes 972 94.5
No 30 2.9
Did not respond 27 2.6
Households with electricity
Yes 984 95.6
No 16 1.6
Did not respond 29 2.8
Households with car/motorcycle 
Yes 676 65.7
No 326 31.7
Did not respond 27 2.6
Household roof material
Cement 982 95.4
Metal sheets, mats, ceramic, shingles 27 2.6
Natural materials 20 1.9
Households with sanitation
No toilet 7 0.7
Household flush to sewer system, septic tank, 
 somewhere else
983 95.5
Household pit latrine, bucket or hanging toilet, 
 communal toilet, other
12 1.2
Did not respond 27 2.6
Drinking water treated at home
Boil 202 19.6
Chlorine liquid, powder, or tablets 15 1.5
Other 5 0.5
Do not treat water 616 59.9
Did not respond 191 18.6
aPatients with blood culture–confirmed Salmonella Typhi or S. Paratyphi resistant to ampicillin, 
chloramphenicol, and cotrimoxazole. It excludes extensively drug-resistant S. Typhi cases.
bPatients with blood culture–confirmed S. Typhi resistant to ampicillin, chloramphen-
icol, cotrimoxazole, or ceftriaxone, and resistant to or with reduced susceptibility to 
fluoroquinolones (ciprofloxacin, levofloxacin, gatifloxacin, moxifloxacin, or ofloxacin). S. 
Paratyphi excluded because there was no extensively drug-resistant case in the sample.
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Of the first-questionnaire respondents, 78.4% had a positive 
blood culture test for S. Typhi, 9.2% had a positive blood culture 
test for S. Paratyphi, and 12.3% had a nontraumatic terminal 
ileal perforation (regardless of blood culture results). Among 
those with a positive blood culture, 170 (18.8%) had MDR en-
teric fever and 401 (44.5%) had XDR typhoid fever. More than 
half were male (60.6%), and 10.4% were younger than 2 years 
old: 19.7% were 2 to 4 years old, 43.7% were 5 to 17 years old, 
and 26.1% were ≥18 years. Nearly all patients’ households had a 
household flush toilet (95.5%), electricity (95.6%), a cement roof 
(95.4%), and a mobile phone (94.5%), but only 21.6% reported 
treating their drinking water by boiling or other methods.
Patient and Caregiver Direct Medical and Nonmedical Costs
Of the 1029 enteric fever patients, 980 (95.2%) reported direct med-
ical costs, of whom 146 (14.2%) reported some inpatient care costs 
(this category includes patients who reported any inpatient care ex-
pense and all patients with nontraumatic ileal perforation; Table 2). 
Across all patients, the median direct medical cost was US $145.98 
(interquartile range [IQR], US $53.51–$387.73). Although not all 
respondents were able to recall the costs they had paid for specific 
procedures, the largest median direct medical cost by procedure sub-
category was inpatient stay (US $74.09; expenditure on bed days, not 
including any other diagnostic or treatment services), followed by 
laboratory results (US $25.66; Figure 1). The costs most frequently 
reported were drugs and medications (reported by 47.0%; median 
cost, US $16.46), registration (reported by 45.9%; median cost, US 
$4.12), and laboratory tests (reported by 25.9%; median cost, US 
$25.66). The median costs were higher in each category for patients 
reporting inpatient care than for patients with only outpatient care.
The median direct nonmedical cost was US $5.35 (IQR, US 
$2.63–$16.46), reported by 832 patients (80.9%; Table 2). Transport 
was the most frequently reported cost of this type (reported by 
99.6% of those with any direct nonmedical costs; median cost, US 
$5.13), but the expenses on food, lodging, and childcare were the 
highest (median cost, US $41.16; reported by 17.3% of patients 
with direct nonmedical costs; Figure  1). The direct nonmedical 
costs of patients reporting inpatient care were higher in all cases 
than the costs of patients only reporting outpatient care.
More than two-thirds of the patients (69.1%) reported direct 
medical and nonmedical costs for seeking care at health facil-
ities before enrollment in the study (Table 2), and 12.1% previ-
ously sought care at pharmacies. The median direct medical and 
nonmedical cost incurred by all patients before enrollment was 
US $24.70 (IQR, US $8.23–$76.55), which represents 15.2% of 
the median total direct medical and nonmedical costs incurred 
over the entire episode of enteric fever up to the second ques-
tionnaire administration date.
Patient and Caregiver Indirect Costs
From illness onset until the time of COI interview at 6 weeks (or 
up to the first questionnaire if the second questionnaire was not 
answered), a median of 3.00 days were spent across 1017 patients 
seeking and receiving care (IQR, 0.17–6.00 days; Table 2; Figure 1). 
A median of 30.00 days of school were lost (IQR, 15.00–50.00 days) 
across 443 patients. A median of 35.00 lost work days (IQR, 14.00–
60.00 days) were reported across 69 patients, and a median of 15.00 
sick leave days were used (IQR, 7.00–28.00 days) across 55 patients. 
On average, patients received care from 2 caregivers. Caregivers for 
997 patients spent a median of 5.00 days (IQR, 0.42–12.00 days) ac-
companying the patient while seeking and receiving care. Caregivers 
for 274 patients were unable to work for a median of 9.00 days (IQR, 
3.00–17.00 days); in addition, caregivers for 231 patients used a me-
dian of 3.00 days of sick leave (IQR, 2.00–6.00 days). When valued at 
the median of patients’ and caregivers’ reported wage ranges, days of 
work lost, plus sick leave, resulted in a median productivity loss of US 
$147.43 (IQR, US $68.79–$287.99) for patients and US $30.19 (IQR, 
US $13.24–$79.44) for caregivers. For patients who received inpa-
tient care, these median indirect costs were higher for all categories 
than for patients only receiving outpatient care.
Median Cost Per Case of Enteric Fever
After adding direct medical costs, direct nonmedical costs, and 
indirect costs of patient and caregiver productivity losses, the me-
dian cost of illness per case of enteric fever from the patient and 
caregiver perspective was US $196.37 (IQR, US $72.89–$496.40) 
for all patients (Table 2; Figure 1). Patients receiving inpatient care 
reported a median COI 3 times higher than that of patients only 
reporting outpatient care. The median COI without the value of 
the sick leave days used decreased by 11%, to US $175.15 (IQR: US 
$64.15–$484.11).
Sensitivity Analysis
The results changed slightly when removing outlier values; the me-
dian COI decreased from US $196.37 to US $178.76 (Table 3). The 
median COI increased by 34% when imputing wages for unpaid 
labor (to US $264.45 for all patients) and by 31% when using the 
national minimum wage rates for unpaid labor of caregivers and 
patients (to US $256.46 for all patients; Table 4). When adding the 
future productivity losses of the 1 patient in the sample who died, 
evaluated at the minimum wage rate, the median COI does not 
change (US $196.37 for all patients; Table 4). When analyzing the 
COIs for typhoid (78.4%) and paratyphoid (9.2%) cases, the re-
sults are qualitatively similar, with higher costs of both the overall 
COI and most subcategories among patients with typhoid (me-
dian COI of US $165.98 for all patients) compared to patients with 
paratyphoid (median COI of US $127.57 for all patients; Tables 5 
and 6). The COI results for patients with nontraumatic ileal per-
foration (12.3%) were higher overall (and in most subcategories of 
direct medical, nonmedical, and indirect costs) than for patients 
without these complications (blood culture–confirmed S. Typhi 
and Paratyphi cases), with an overall median COI of US $508.49, 
which is 3 times higher than for typhoid cases and 4 times higher 
than for paratyphoid cases (Tables 5–7). Given the high cost of 
surgical cases, when they are removed from the analysis the me-
dian COI for all patients (combined blood culture–confirmed S. 
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Typhi and Paratyphi cases) decreases to US $155.73 (Table 7). The 
COI results for patients with MDR enteric fever (median COI, US 
$133.50) were lower than that for all patients in the sample (US 
$196.37), while the COI results for patients with XDR typhoid 
fever (median COI, US $251.34) were higher than that for all pa-
tients in the sample, but lower than for patients with nontraumatic 
ileal perforation (median COI, US $508.49; Tables 7–9).
Cost of Illness From the Health Care Provider Perspective
The average direct medical costs per case of enteric fever from the 
provider’s perspective were US $50.88 for Hospital A, US $52.24 
for Hospital B, and US $11.73 for Hospital C (Hospital C in-
cludes only the costs of medical services specific to enteric fever; 
Table 10). The costliest procedures at Hospital A were a pediatric 
intensive care unit bed day (US $256.92), followed by an inpatient 
hospital bed day (US $71.75) and gallbladder surgery (US $64.76). 
The least costly procedures were a blood draw (US $1.42) and ab-
dominal ultrasound (US $2.14). In Hospital B, the most expensive 
procedures were an intensive care unit bed day (US $162.24), an 
emergency visit (US $35.43), and an inpatient hospital bed day 
(US $12.36), while the least costly were a blood draw (US $1.98) 
and an abdominal X-ray (US $4.93). In Hospital C, the most ex-
pensive procedures were surgery for intestinal perforation (US 
$151.28) and gallbladder surgery (US $107.41), while the least 
costly was a blood draw (US $0.94). Data on the frequencies of 
some specific procedures were not available from the surveillance 
component.
DISCUSSION
This study found that costs related to enteric fever were con-
siderable among the sample of patients in Pakistan, particularly 
among those with severe complications (surgical and XDR ty-
phoid cases). Compared with the existing literature on patient 
and caregiver COI estimates, this study found direct medical 
and nonmedical costs that were almost 6 times higher than the 
Figure 1. Distribution of cost-of-illness elements from the patient and caregiver perspective, Karachi, Pakistan, September 2016–December 2018. N = 1029 patients. Data 
are in 2018 US$.
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previous published estimates for Pakistan (Table 11) [7–9, 19]. 
Similarly, within our SEAP country studies, the direct medical 
and nonmedical COI for Pakistan was higher when compared 
with Bangladesh and Nepal (Table 11) [10, 11]. Although this 
study found average indirect costs higher than those previously 
available for Pakistan, these were lower than the indirect costs 
in studies conducted in Tanzania and Indonesia. The higher 
direct medical and nonmedical costs found here reflect differ-
ences in the structures of the health  care systems and organ-
izations included in each study, as well as potentially higher 
health  care prices at the time of this study versus when data 
were collected for most previous studies in 1995–2003, even 
after adjusting for inflation. The lower indirect costs in this 
study might be due to differences in the definition of indirect 
costs; specifically, this study only monetized the productivity 
losses related to work time and sick leave of patients and care-
givers ≥18 years, whereas other studies monetized productivity 
losses due to work time, sick leave, and school days of all ages, 
including those <18 years.
The median direct medical costs for all patients and care-
givers in our sample, for patients reporting inpatient care costs, 
and for patients reporting only outpatient costs were 340.7%, 
550.4%, and 294.7%, respectively, of Pakistan’s all-source health 
expenditure per capita of US $42.85 (2016 value in 2018 US 
dollars [4]). This illustrates the considerable economic burden 
posed by enteric fever in this country. Compared with the 
annualized median wage rates reported in the sample of US 
$1906.67, the median direct medical and nonmedical costs per 
case represented approximately 8.2%, 15.6%, 15.5%, 5.6%, and 
10.8% of the annual individual labor income for all patients, 
for patients reporting inpatient care costs, for patients with 
nontraumatic ileal perforation, for patients with MDR enteric 
fever, and for patients with XDR typhoid fever, respectively. The 
literature defines catastrophic health expenditures as COIs that 
exceed 10% of the annual household income [20–22]. The esti-
mated direct medical and nonmedical costs per case of enteric 
fever estimated by this study for patients receiving inpatient 
care would be considered catastrophic if the patients and care-
givers who reported productivity losses were the only income 
earners in their households (household income was not meas-
ured in this COI study).
Limitations
This study has several limitations. Eligible patients included 
those with nontraumatic terminal ileal perforation, which 
sometimes follows acute enteric fever cases; although those 
with a known alternative diagnosis were excluded, it is pos-
sible that some might have been misclassified. In the patient 
and caregiver COI sample, 12.3% of patients had such per-
forations and negative blood culture results, providing a max-
imum bound on the potential inclusion of non–enteric fever 
patients in the main analysis with all patients. The patient and 
Table 10. Health Care Provider Cost of Illness Due to Enteric Fever: Procedure Unit Costs and Frequencies, and Average Cost Per Case of Enteric Fever, 
Karachi, Pakistan, July 2015–June 2016 
Procedure
 Unit cost in 2018 US$ Frequency 
Hospital Aa Hospital Ba Hospital Ca Hospital Aa Hospital Ba Hospital Ca
General services not specific to enteric fever
Pediatric intensive care unit, per patient, per day $256.92 N/A N/A ...b N/A N/A
Intensive care unit, per patient, per day N/A $162.24 ...b N/A ...b ...b
Inpatient hospital cost, per patient, per day $71.75 $12.36 ...b 0 1165 590
Surgical inpatient, per patient, per day $44.15 $11.98 ...b 0 0 4
Surgical outpatient visit, per patient, per visit $6.52 $12.08 ...b 22 1 1
Emergency, per patient, per visit $5.23 $35.43 ...b ...b ...b ...b
Outpatient routine service cost, per patient, per visit $4.33 $21.18 ...b 0 168 231
Services specific to enteric fever
Gallbladder surgery $64.76 ...b $107.41 ...b ...b ...b
Surgery for intestinal perforation $40.58 ...b $151.28 73 17  1
Complete blood count ...b ...b ...b 21 418 115
Blood culture $23.28 $11.76 $10.25 22 497 365
Abdominal X-rayc  $3.60 $4.93 $3.80 11 123 8
Abdominal ultrasound $2.14 $7.07 $2.11 12 84 7
Blood draw $1.42 $1.98 $0.94 22 478 365
Total blood culture–confirmed enteric fever or nontraumatic ileal perforation cases … … … 73 497 365
Weighted average cost per case by enrollment site $50.88 $52.24 $11.73 … … …
N = 935. 
Abbreviations: N/A, not applicable because this hospital does not offer that service. 
a Hospital A is a public-sector, not-for-profit pediatric hospital with teaching status; Hospitals B and C are private, not-for-profit teaching hospitals.
b Missing information.
c Based on number of chest X-rays as a proxy, as number of abdominal X-rays was not collected in the Surveillance for Enteric Fever in Asia Project (SEAP) II clinical surveillance component.
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site samples are not representative of Pakistan, and only reflect 
patients who sought care at the sampled hospitals. Thus, care 
should be taken in generalizing results of this study beyond 
similar populations. Self-reported patient and caregiver costs 
may also be subject to recall or reporting bias. Patient and 
caregiver COI interviews were conducted by phone instead 
of in person, which could have affected the response rate. 
A control group to account for potential background patient 
morbidity and health care costs was not included. The study 
does not model the risk of increasing antimicrobial-resistant 
enteric fever and its associated costs.
Among the limitations of the health care provider COI is the im-
putation of some medical supply prices and administrative costs 
based on third-party sources (eg, other hospitals and UNICEF), 
which may have increased or decreased the estimated costs com-
pared to the real prices. Some elements of the health care provider 
COI (eg, personnel time per procedure) may be subject to recall or 
reporting biases, which may over- or underestimate the COI.
Finally, costs were not combined across perspectives due to the 
limited health facility sample, which did not represent all health fa-
cilities visited by patients at which patient and caregiver costs were 
incurred, and the limited ability of patients and caregivers to recall 
and report expenses for specific clinical procedures (eg, by specific 
type of lab test) to match these with health facility costs.
CONCLUSIONS
The COI estimates presented here illustrate that the economic 
burden of enteric fever is considerable to patients, their caregivers, 
and health care providers in Pakistan, especially for cases with com-
plications, such as nontraumatic ileal perforation. In combination 
with other evidence on the disease burden and the costs and ef-
fectiveness of interventions, understanding the magnitude of the 
economic burden of enteric fever is important to assess the value 
of interventions aiming to control enteric fever, and to inform pro-
grammatic and strategic decisions around typhoid Vi-conjugate 
vaccine introduction strategies and improvements to water and 
sanitation in Pakistan and other endemic countries.
Notes
Acknowledgments. The authors thank the Surveillance for Enteric Fever in Asia 
Project (SEAP) Pakistan team, especially Irum Fatma, Hina Mirza, Najeeb Rahman, 
and Ashar Malik; personnel in the SEAP Pakistan study sites; personnel at the 
International Centre for Diarrhoeal Disease Research, Bangladesh; and other mem-
bers of the SEAP project team who supported data collection and management, 
especially Ashley Tate Longley and Caitlin Barkume.
Disclaimer. The results and conclusions in this article are those of the au-
thors and do not necessarily represent the official position or policies of the 
US Centers for Disease Control and Prevention or other partners.
Financial support. This work was supported by funding from the Bill 
and Melinda Gates Foundation (Investment ID grant number INV-008335) 
and the US Centers for Disease Control and Prevention. 
Supplement sponsorship.  This supplement is sponsored by the Sabin 
Vaccine Institute and made possible by a grant from the Bill & Melinda 
Gates Foundation.
Potential conflicts of interest. K. D., T. A., S. P., and N. M. report a condi-
tional gift agreement between the Sabin Vaccine Institute (Primary grantee 
for the Surveillance for Enteric Fever in Asia Project grant from the Bill and 
Melinda Gates Foundation) and the CDC Foundation. All other authors 
report no potential conflicts. All authors have submitted the ICMJE Form 
for Disclosure of Potential Conflicts of Interest. Conflicts that the editors 
consider relevant to the content of the manuscript have been disclosed.
References
1. Global Burden of Disease 2017 Typhoid and Paratyphoid Collaborators. The 
global burden of typhoid and paratyphoid fevers: a systematic analysis for the 
Global Burden of Disease Study 2017. Lancet Infect Dis 2019; 19:369–81.
2. Haddix AC, Teutsch SM, Corso PS. Prevention effectiveness: a guide to decision 
analysis and economic evaluation. New York, NY: Oxford University Press, 2003.
3. World Health Organization. Antimicrobial resistance: global report on surveil-
lance. Geneva, Switzerland: World Health Organization, 2014.
4. World Bank. World development indicators. 2019. Available at: https://
datacatalog.worldbank.org/dataset/world-development-indicators. Accessed 7 
November 2019.
5. Institute for Health Metrics and Evaluation. Global health data exchange. Global 
Burden of Disease study 2017. 2020. Available at: http://ghdx.healthdata.org/gbd-
2017. Accessed 15 January 2020.
6. Gavi The Vaccine Alliance. Pakistan becomes first country to introduce new ty-
phoid vaccine into routine immunisation program. 2019. Available at: https://
www.gavi.org/news/media-room/pakistan-becomes-first-country-introduce-
new-typhoid-vaccine-routine-immunisation#:~:text=Pakistan%20becomes%20
first%20country%20to%20introduce%20new%20typhoid,vaccine%20to%20
offer%20protection%20against%20increasingly%20drug-resistant%20disease. 
Accessed 25 February 2020.
7. Poulos C, Riewpaiboon A, Stewart JF, et al. Cost of illness due to typhoid fever in 
five Asian countries. Trop Med Int Health 2011; 16:314–23.
8. Bahl R, Sinha A, Poulos C, et al. Costs of illness due to typhoid fever in an Indian 
urban slum community: implications for vaccination policy. J Health Popul Nutr 
2004; 22:304–10.
9. Kaljee LM, Pach A, Garrett DO, Bajracharya D, Karki K, Khan I. Social and ec-
onomic burden associated with typhoid fever in Kathmandu and surrounding 
areas: a qualitative study. J Infect Dis 2017; 218:S243–9.
10. Mejia  N, Pallas  SW, Saha  S, et  al. Typhoid and paratyphoid cost of illness in 
Bangladesh: patient and health facility costs from the Surveillance for Enteric 
Fever in Asia Project (SEAP) II. Clin Infect Dis 2020.
11. Mejia N, Abimbola T, Andrews J, et al. Typhoid and paratyphoid cost of illness in 
Nepal: patient and health facility costs from the Surveillance for Enteric Fever in 
Asia Project (SEAP) II. Clin Infect Dis 2020.
12. World Health Organization. Typhoid vaccines: WHO position paper–March 
2018. Wkly Epidemiol Rec 2018; 13:153–72.
13. Aguinis  H, Gottfredson  RK, Joo  H. Best-practice recommendations for 
defining, identifying, and handling outliers. Organ Res Methods 2013; 
16:270–301.
14. Employers Federation of Pakistan.  Sindh minimum Wage Notification 8 October 
2018.  2018. Available at: https://efp.org.pk/sindh-minimum-wage-notification-
8-october-2018/. Accessed 28 October 2020.
15. World Health Organization. WHO global observatory data repository–life ex-
pectancy by country. 2016. Available at: http://apps.who.int/gho/data/node.
main.688?lang=en. Accessed 20 March 2020.
16. Pakistan Bureau of Statistics. Consumer price index. 2019. Available at: http://
www.sbp.org.pk/ecodata/MPM.pdf. Accessed 7 November 2019.
17. National Bank of Pakistan. Exchange rates. 2019. Available at: https://www.nbp.
com.pk/RateSheet/index.aspx. Accessed 7 November 2019.
18. United Nations International Children’s Emergency Fund. Supply catalog. 2019. 
Available at: https://supply.unicef.org/. Accessed 15 October 2019.
19. Riewpaiboon  A, Piatti  M, Ley  B, et  al. Cost of illness due to typhoid fever in 
Pemba, Zanzibar, East Africa. J Health Popul Nutr 2014; 32:377–85.
20. Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJ. Household 
catastrophic health expenditure: a multicountry analysis. Lancet 2003; 
362:111–7.
21. Xu K, Evans DB, Carrin G, Aguilar-Rivera AM, Musgrove P, Evans T. Protecting 
households from catastrophic health spending. Health Aff (Millwood) 2007; 
26:972–83.
22. Raban MZ, Dandona R, Dandona L. Variations in catastrophic health expendi-
ture estimates from household surveys in India. Bull World Health Organ 2013; 
91:726–35.
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/article/71/Supplem
ent_3/S319/6013571 by Aga Khan U
niversity, Karachi user on 16 D
ecem
ber 2020
